Background: In allergic responses a distinction is made between an early phase
Introduction
Allergic rhinitis (AR) is an inflammatory condition in which symptoms are not confined to an early phase response within minutes after allergen exposure, but may be present several hours after allergen contact (late phase response).
Symptoms of the early phase response are sneezing, itching and rhinorrhea.
During the late phase response congestion, fatigue, malaise, and irritability become more prominent. During this late phase, inflammatory cells such as eosinophils and T cells infiltrate the mucosa. Especially Th 2 cytokines, such as IL-4, IL-5 and IL-13, play a central role in the late phase allergic response. [1] [2] [3] As in AR, early and late inflammatory changes in the bronchi of asthmatic patients, with influx of activated eosinophils and T cells, can be demonstrated. [4] [5] [6] Both nasal and bronchial mucosa are elements of a "united airway" and therefore AR and asthma are both manifestations of the same allergic disease. 4 As a consequence, asthma and rhinitis often coexist in the same patients. It appears that at least 80% of asthmatic patients suffer from rhinitis and around 20-30% of patients with AR also have asthma. 2, 7 In vivo skin testing or detection of in vitro allergen-specific responses can be helpful to test whether a patient with a relevant clinical history is allergic to a specific allergen. After intradermal injection of allergen in the skin of a sensitive subject a type-I reaction develops rapidly, peaks after 10-20 min, and subsides within a few hours. After several hours a late diffuse edematous response may appear at the allergen injection site. 8 In vitro, allergen-specific T cell responses and Th 2 cytokine production can be assessed. 
Methods and subjects

Patient selection
Fifty-nine children (aged 6 to 18 years) with allergic rhinitis and established HDM allergy were selected from electronic medical records in general practice.
The inclusion criteria were: presence of specific IgE antibodies to HDM in serum (≥ 0.7 kU/l), a history of allergic rhinitis during at least 1 year, and a nasal symptom score of at least 4 out of 12 (see below). Before scoring symptoms, nasal corticosteroids were withheld for 4 weeks before the study period. The presence of asthma was assessed using the International Study of Asthma and Allergies in Childhood (ISAAC) core questionnaire. 9 The study was approved by the ethical review board of Erasmus MC. All patients and / or their parents gave informed consent for the study.
Measurement of nasal or asthma symptoms
All participants or their parents scored their nasal symptoms on diary cards during a period of 1 month in October or in November. Nasal symptoms (sneezing, itching nose, watery running nose and nasal blockage) were scored on a 0-3 scale (0=none, 1=mild, 2=moderate, 3=severe). In total, a maximal daily cumulative nasal symptom score of 12 could thus be obtained. Children or parents scored their asthma symptoms (wheeze/breathless and dry cough during night) daily during 1 month on diary cards. In total, a maximum daily asthma symptom score of 6 (0-3 for wheeze/breathless and 0-3 for dry cough during night) could be obtained. 
Skin testing
Allergy skin testing was performed by intracutaneous injection of 0.02 ml Dermatophagoides pteronyssinus in the forearm (concentration 30 U/ml, manufactured by ALK-Abelló, Nieuwegein, the Netherlands). We chose to perform an intracutaneous skin test rather than the usual skin prick test because intracutaneous injection of the allergen is the most feasible and convenient way to induce a late phase response after the early phase skin response. 8 As a positive control, histamine (concentration 0.01 mg/ml) was injected, negative control was dilution buffer. Reactions were read after 15 min (early response) and after 6 h (late response). The area of the skin response in mm 2 was measured by a specially developed scanning program. The early phase response was considered positive when its size was at least half the size of the histamine response (expressed as a Histamine-Equivalent-IntraCutaneous index or HEIC index). This cut-off value was determined by applying a modified algorithm proposed by Niemijer et al. 10 Late phase skin responses with a surface of more than 100 mm 2 were regarded positive, a surface of 50-100 mm 2 was considered borderline. Children were not allowed to take antihistamines within 24 h prior to skin testing.
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HDM-specific T cell proliferation
Blood was drawn before skin testing. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by density centrifugation on 
HDM-specific cytokine production
To determine HDM-specific cytokine production, 1 ml of PBMCs with a concentration of 2x10 6 
Statistical analysis
Associations between variables were assessed using Spearman's correlation coefficient (r s ), since data were not normally distributed. A p-value of 0.05 (2-sided) was considered to be the limit of significance in all analyses. SPSS 11.0
for Windows was used for all analyses.
Results
Clinical characteristics of the study population
Baseline characteristics of the 59 children are summarized in Table 1 . All children had elevated serum concentrations of HDM-specific IgE antibodies (mean 43.2 kU/l, range 0.7 to >100 kU/l). The mean daily nasal symptom score was 3.4 (range 0.3 to 8.8). Of the 59 children, 27 (46%) reported an earlier physician's diagnosis of asthma. However, 70% of children reported wheeze.
The mean asthma symptom score was 0.9 (range 0 to 5.4) for the total group.
Patients diagnosed as having asthma had an asthma symptom score of 1.4 whereas children without asthma had a score of 0.4 (p=0.002).
The early phase skin response to HDM was determined in 52 patients only. A positive response was detected in 51/52 patients (98%). Of the 59 children, 48
(81%) had a positive late phase skin response and 7/59 (12%) had a borderline positive late response.
Correlation between in vivo skin tests and in vitro T cell responses
Positive HDM-specific T cell proliferation responses were found in 51/59 (86%)
and Th 
Correlation between skin responses and nasal or asthma symptoms
The early phase skin response correlated with the nasal symptom score fig 2c) .
Correlation between T cell responses and nasal or asthma symptoms
Allergen-specific T cell proliferation was associated with asthma symptoms 12 Especially IL-5 is responsible for the cascade of eosinophil activation, whereas IL-13 and IL-4 are crucial in IgE production. 13 Whereas an association emerged between the extent of a late phase skin response and the level of the in vitro T cell proliferation, no correlation was found between the extent of the late phase skin reaction and production of Th 2 cytokines. So, whereas there is an involvement of allergenspecific T cells in the late phase response, we were not able to attribute this to Th 2 cells in particular.
Other studies report a lack of correlation between absolute amounts of IL-5 or IL-13 secretion and proliferative responses. 14,15 Perhaps a combination of qualitative (i.e. cytokine profiles) and quantitative responses (i.e. proliferation rate) serve to characterize the allergic responder phenotype.
It is possible that cytokines were derived from basophils rather than T cells. A correlation between late asthmatic response (LAR) and inflammation (i.e.
allergen-specific proliferative response of T cells) has been reported. 16 However, no contribution of the late cutaneous response was found in association with LAR or inflammation; the lack of a relationship between allergen-induced late inflammatory response in the skin and airways in the latter study could be explained by variations in measurement.
Very few studies have addressed the association between clinical symptoms and the outcome of in vivo and in vitro tests. In two studies the severity of asthma appeared to be associated with the number of positive skin tests and the magnitude of the immediate skin reaction 17 or with total and specific IgE. 18 In seasonal allergic rhinitis skin tests do not predict symptom severity in the pollen season.
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More research has focused on the relationship between in vivo or in vitro tests and allergen-specific bronchial 16, [20] [21] [22] or nasal 22 airway reactivity.
In line with previous challenge studies 16,21 our results suggest that asthmatic complaints are related to late inflammatory changes, i.e. the level of allergenspecific proliferative response of T cells in vitro and the late phase cutaneous response in vivo. In our study, the early skin response is not correlated with asthmatic complaints, but with nasal symptoms, whereas the late phase cutaneous reaction was not related with rhinitis severity. Also, the nasal allergic reaction is better predicted by immediate skin test than by late skin reactions. 23 However, all challenge studies demonstrate that non-specific airway reactivity is more important in predicting airway reactivity to allergens than indices of allergic sensitization. This might, in part, explain the weak correlations found in the present study.
Whereas in both AR and asthma early and late phase responses play an important role, 24 it seems feasible that sneezing and itching are features of an early phase response, and that during the late phase response asthma and nasal congestion are more prominent. During the early phase response, histamine and leukotrienes are important mediators that are generated from resident airway cells. Therefore, antihistamines and anti-leukotrienes are effective against direct complaints of the nose and the early skin response. 5 
Limitations of the study
Correlations in our study were significant but not strong. This might be explained by the fact that the complaints of patients are determined by many factors, such as degree of sensitization, allergen exposure, non-specific airway hyperresponsiveness, experience, use of specific medication, and symptom perception. Since the interaction between all these variables influences the outcome, we would not expect a high correlation coefficient.
Another explanation might be that children were allowed to take symptomatic asthma or allergy medication in case of complaints. This might result in a decrease of self-reported symptoms, and a weaker correlation between T cell responses and symptoms. 
